MIM
DYN icon

Monashee Investment Management’s Dyne Therapeutics DYN Stock Holding History

Monashee Investment Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-114,525
Closed -$2.24M – 48
2025
Q4 		$2.24M Buy
+114,525
New +$2.17M 1.26% 26
2024
Q3 		– Sell
-85,000
Closed -$3M – 121
2024
Q2 		$3M Sell
85,000
-85,000
-50% -$2.47M 0.39% 34
2024
Q1 		$4.83M Buy
+170,000
New +$3.84M 0.57% 31
2023
Q1 		– Sell
-123,719
Closed -$1.43M – 62
2022
Q4 		$1.43M Sell
123,719
-76,281
-38% -$883K 0.62% 35
2022
Q3 		$2.54M Sell
200,000
-119,536
-37% -$1.37M 0.94% 16
2022
Q2 		$2.19M Buy
319,536
+39,832
+14% +$274K 0.8% 12
2022
Q1 		$2.7M Buy
279,704
+184,404
+193% +$1.57M 0.78% 15
2021
Q4 		$1.13M Buy
+95,300
New +$1.34M 0.28% 37
2020
Q4 		– Sell
-107,735
Closed -$2.17M – 292
2020
Q3 		$2.17M Buy
+107,735
New +$2.36M 0.47% 54

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Monashee Investment Management's DYN Position: Q1 2026 in Review

Monashee Investment Management sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 114,525 shares — an estimated $2.24M sold.

Monashee Investment Management first reported a position in DYN in Q3 2020 and held it in 9 quarters. The position peaked at $4.83M in Q1 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Monashee Investment Management reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Monashee Investment Management sold 114,525 Dyne Therapeutics shares in Q1 2026, an estimated $2.24M.
  • Monashee Investment Management first reported a position in Dyne Therapeutics in Q3 2020 and held it in 9 quarters.
  • Monashee Investment Management's Dyne Therapeutics position peaked at $4.83M in Q1 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.